Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has earned a consensus recommendation of “Buy” from the twenty-six ratings firms that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation, fifteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $127.03.
ALNY has been the subject of several research analyst reports. FBR & Co initiated coverage on Alnylam Pharmaceuticals in a research report on Monday, October 30th. They issued a “buy” rating and a $150.00 price objective for the company. B. Riley initiated coverage on Alnylam Pharmaceuticals in a research report on Wednesday, November 1st. They issued a “buy” rating and a $240.00 price objective for the company. Piper Jaffray Companies reissued an “overweight” rating and issued a $14.71 price objective (down from $188.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, November 2nd. Needham & Company LLC reissued a “buy” rating and issued a $152.00 price objective (up from $125.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Finally, Cowen reissued an “outperform” rating and issued a $151.00 price objective (up from $117.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd.
In other Alnylam Pharmaceuticals news, VP Michael Mason sold 36,745 shares of the business’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the completion of the sale, the vice president now directly owns 6,352 shares of the company’s stock, valued at approximately $835,859.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Laurie Keating sold 6,249 shares of the business’s stock in a transaction that occurred on Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total value of $757,378.80. Following the sale, the senior vice president now directly owns 17,749 shares of the company’s stock, valued at $2,151,178.80. The disclosure for this sale can be found here. Insiders have sold a total of 72,994 shares of company stock valued at $9,669,353 over the last three months. Corporate insiders own 4.30% of the company’s stock.
Alnylam Pharmaceuticals (NASDAQ ALNY) traded up $1.58 during mid-day trading on Friday, hitting $123.00. The stock had a trading volume of 564,800 shares, compared to its average volume of 821,746. Alnylam Pharmaceuticals has a 1 year low of $46.90 and a 1 year high of $147.63. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.23 and a current ratio of 12.23. The company has a market cap of $12,150.00, a price-to-earnings ratio of -22.80 and a beta of 2.68.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative return on equity of 41.08% and a negative net margin of 545.95%. The business had revenue of $37.90 million during the quarter, compared to the consensus estimate of $19.31 million. During the same period last year, the business posted ($1.32) earnings per share. The business’s revenue was up 116.6% on a year-over-year basis. equities analysts forecast that Alnylam Pharmaceuticals will post -6.88 earnings per share for the current year.
WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) Receives $127.03 Consensus PT from Brokerages” was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3225965/alnylam-pharmaceuticals-inc-alny-receives-127-03-consensus-pt-from-brokerages.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.